101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020
SB3659

 

Introduced 2/14/2020, by Sen. Melinda Bush

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/322 new

    Amends the Illinois Controlled Substances Act. Provides that a prescriber shall offer a prescription for naloxone hydrochloride, or another similar drug approved by the Food and Drug Administration, under specified circumstances. Provides for educational information to be provided concerning overdose prevention and the use of naloxone hydrochloride. Provides that a prescriber who does not comply with specified requirements shall be subject to administrative sanctions under the appropriate licensing board. Specifies that the provisions do not create a private right of action against a prescriber, and do not limit a prescriber's liability for the negligent failure to diagnose or treat a patient.


LRB101 18151 RLC 67592 b

 

 

A BILL FOR

 

SB3659LRB101 18151 RLC 67592 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by adding Section 322 as follows:
 
6    (720 ILCS 570/322 new)
7    Sec. 322. Naloxone hydrochloride prescription.
8    (a) Notwithstanding any provision of law to the contrary, a
9prescriber shall:
10        (1) offer a prescription for naloxone hydrochloride or
11    another drug approved by the United States Food and Drug
12    Administration for the complete or partial reversal of
13    opioid depression to a patient when one or more of the
14    following conditions are met:
15            (i) the prescription dosage for the patient is 90
16        or more morphine milligram equivalents of an opioid
17        medication per day;
18            (ii) an opioid medication is prescribed
19        concurrently with a prescription for benzodiazepine;
20        or
21            (iii) the patient presents with an increased risk
22        for overdose, including a patient with a history of
23        overdose, a patient with a history of substance use

 

 

SB3659- 2 -LRB101 18151 RLC 67592 b

1        disorder, or a patient at risk for returning to a high
2        dose of opioid medication to which the patient is no
3        longer tolerant;
4        (2) consistent with the existing standard of care,
5    provide education to patients receiving a prescription
6    under paragraph (1) of this subsection (a) on overdose
7    prevention and the use of naloxone hydrochloride or another
8    drug approved by the United States Food and Drug
9    Administration for the complete or partial reversal of
10    opioid depression; and
11        (3) consistent with the existing standard of care,
12    provide education on overdose prevention and the use of
13    naloxone hydrochloride or another drug approved by the
14    United States Food and Drug Administration for the complete
15    or partial reversal of opioid depression to one or more
16    persons designated by the patient, or, for a patient who is
17    a minor, to the minor's parent or guardian.
18    (b) A prescriber who does not comply with the requirements
19of this Section shall be subject to administrative sanctions
20under the appropriate licensing board. This Section does not
21create a private right of action against a prescriber, and does
22not limit a prescriber's liability for the negligent failure to
23diagnose or treat a patient.